Search Results

Despite a $400 million impairment charge, analysts say the removal of a drug-device combo from its portfolio is not a huge loss for Vertex given that the company has a more advanced type 1 diabetes candidate in zimislecel.

Ascensia Diabetes Care, a global diabetes care company, makers of CONTOUR® blood glucose monitoring system portfolio and distributors of the Eversense® continuous glucose monitoring system, was named as an honoree at the Joslin Diabetes Center High Hopes Gala, to celebrate the 100th Anniversary of Insulin, held on November 13th.

In a paper published in Science Translational Medicine, researchers from City of Hope®, one of the largest cancer research and treatment organizations in the United States and a leading research center for diabetes and other life-threatening illnesses, report that they have discovered advances in predicting kidney failure in type 1 diabetes patients.

Roughly 11 percent of people living in the United States have type 2 diabetes and nearly 40 percent of adults have prediabetes, according to the Centers for Disease Control and Prevention.

Eli Lilly’s shares shot up 11% pre-market on Thursday after orforglipron became the first small-molecule GLP-1 drug to ace a late-stage study in type 2 diabetes, eliciting significant reductions in body weight and improvements in glucose control.

Joslin Diabetes Center is providing notice of a cyber incident that may affect the security of some information relating to certain individuals associated with Joslin, including donors and patients.